The prostate cancer became for two decades the most frequent cancer in men. We describe the evolution of its incidence and mortality from 1980 to 2011 for France.
METHODS - Incidence data were collected from registries and national incidence estimates were based on the use of mortality as a correlate of incidence.
RESULTS - After a very strong increase of incidence between 1980 (24.8/100,000) and 2005 (124.5/100,000), we observe a net decline since (97.7/100,000, in 2011). The reduction began earlier for the old patients. The evolution of mortality is very different. We observe a regular reduction since the end of 1990s (from 18.0/100,000 in 1990 to 10.5/100,000 in 2011). The reduction began earlier for the young patients.
CONCLUSIONS - This pattern of evolution is observed in all the countries where the use of the PSA had caused an important increase of the diagnosis of prostate cancer.
Prog Urol. 2015 Jul;25(9):536-42. doi: 10.1016/j.purol.2015.04.011. Epub 2015 Jun 1.
[Article in French]
Grosclaude P1, Belot A2, Daubisse Marliac L3, Remontet L2, Leone N4, Bossard N2, Velten M5; le réseau Francim.
1 UMR1027, université de Toulouse III, 31062 Toulouse, France; IUC, Registre des cancers du Tarn, 31300 Toulouse, France.
2 Service de biostatistique, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69424 Lyon, France; Université de Lyon-I, 69622 Villeurbanne, France; CNRS, UMR 5558, laboratoire biostatistique santé, 69495 Pierre-Bénite cedex, France.
3 UMR1027, université de Toulouse III, 31062 Toulouse, France; IUC, Registre des cancers du Tarn, 31300 Toulouse, France.
4 Registre des cancers du Limousin, 87000 Limoges, France.
5 EA 3430, registre des cancers du Bas-Rhin, laboratoire d'épidémiologie et de santé publique, faculté de médecine, université de Strasbourg, 67085 Strasbourg, France.